Prevents pregnancy. ANDA 91425, held by Lupin Ltd. Ethinyl Estradiol; Levonorgestrel.
As of Nov 16, 2026, ANDA 91425 (Levonorgestrel And Ethinyl Estradiol), held by Lupin Ltd, was first approved by FDA on Jan 18, 2013, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Levonorgestrel and ethinyl estradiol tablets USP, 0.1 mg and 0.02 mg are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table II lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and Norplant System, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 18, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levonorgestrel And Ethinyl Estradiol0.02MG;0.1MG · tablet;oral-28 | Ethinyl Estradiol; Levonorgestrel | Rx |
| Apr 29, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 18, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters